Crispr Therapeutics Ag (CRSP)
$65.36 0.67 (1.01%)
19:46 EST CRSP Stock Quote Delayed 15 Minutes
Previous Close $65.36
Market Cap 3.06B
PE Ratio -
Volume (Avg. Vol.) 739,800
Day's Range 64.35 - 67.37
52-Week Range 22.22 - 74.00
Dividend & Yield N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ag News
- From InvestorPlace
- From the Web
It's no secret Matt McCall is searching for emerging trends. This week, he discusses cannabis stocks and a breakthrough biotech therapy.
CRISPR is a great addition to your stock wish list. If we get a correction, this is a solid long-term addition to your portfolio.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.
If you're looking for biotech stocks to buy with massive breakthrough potential in gene editing, then these three are kings among the rest.
Even by biotech standards, CRSP stock is volatile and prone to snap reactions -- but the potential rewards are huge.
These three high-reward stocks, each with their own emerging trend, that have huge upside potential in the transformative years ahead.
Crispr stock is down 7% on the release of a new study. But the headline is not nearly as scary as it sounds.
Although Crispr’s gene splicing techniques are revolutionary, the rally in CRSP stock is coming to an end as investors question its valuation.
Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio. Compare Brokers....
These 4 names are the best stocks to buy right now, each offering something most other stocks don't.
Crispr stock is riding a euphoric wave thanks to the biotech firm’s innovations. But what is CRISPR and what are the downsides?
From Talk Markets
Navellier RatingsPowered by Portfolio Grader